Therefore, this study intends to analyze the effects of SHR-1210 combined with chemotherapy on SCC and VEGF levels, cyclic survival rate, progression free survival (PFS), and adverse reaction rate in advanced lung squamous cell carcinoma at the clinical level, so as to provide a better data model for the clinical treatment of advanced lung squamous cell carcinoma. This evidence concerns the gene VEGFA and squamous cell lung carcinoma.